Fig. 4

Distribution of BES values and ranks in experimental cohort for all lines of therapy (ae, n = 30; bf, n = 30) and for first lines of therapy (cg, n = 12; dh, n = 12). Drug ranks were BES ranks among all drugs in a given patient. Color in a-d denotes drugs approved for CRC and experimental therapeutics. Color in a-d denotes drugs approved for CRC and experimental therapeutics. Color in e-h denotes treatment response. Responders group included patients with partial response and stable disease, non-responders group included progressive disease patients